choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Pharmaceutical Industry Second Half Profits

Pharmaceutical Industry Second Half Profits Newsletter
  • Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution 23 Apr 2024 11:30 GMT

    … in the second half of … collaboration profitability, compared …                   KINIKSA PHARMACEUTICALS, LTD. CONSOLIDATED STATEMENTS OF OPERATIONS …   March 31,                 2024   2023 Revenue:                     Product revenue, net   $ 78,885     $ …

  • Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts 22 Apr 2024 21:22 GMT

    … April 19th, shares of Hookipa Pharma (NASDAQ:HOOK) closed at $0 … for HB-200 in the second half of this year. Clinical HOOK … initial costs, but bring in revenue perhaps 2 years faster? Equally … in 1L HBV16+ HNSCC (Hookup Pharma';s 03/24 …

  • Baron Health Care Fund Q1 2024 Shareholder Letter 23 Apr 2024 14:48 GMT

    … operating margin expansion. Within pharmaceuticals, not owning certain … ), argenx, and Vertex Pharmaceuticals Incorporated (VRTX) also underperformed … better revenue growth. They may not be profitable today, … improving trends in the second half of 2024 and …

  • Danaher Corporation (DHR) Q1 2024 Earnings Call Transcript 23 Apr 2024 14:48 GMT

    … and core revenue declined 4%. Geographically, core revenues in developed … remains challenging. Our gross profit margin for the first … in the second half of 2023. In developed markets, pharma and biotech … . But then in the second half, we should see some …

  • Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results 23 Apr 2024 14:48 GMT

    … margins and increased long-term profits. Generics are also a … more promising products for the second half of the decade, and … generic competition. Full year revenue and operating income growth guidance … pure-play, high-margin pharma company with a strong …

  • Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy? 18 Apr 2024 12:47 GMT

    … its pipeline. Biotech giant Vertex Pharmaceuticals (VRTX -0.27%) … past six months, the drugmaker has earned important regulatory approvals … for this candidate in the second half of the year. Vertex … decade, Vertex's revenue and earnings continue moving in …

  • NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates 17 Apr 2024 21:38 GMT

    … Life, a not-for-profit spinal cord injury research … Kelly brings three decades of pharmaceutical experience, playing instrumental roles … trial that commenced in the second half of 2023.   G… limitation, a lack of revenue, insufficient funding, the impact …

  • Research houses reiterate ‘overweight’ call on healthcare sector 23 Apr 2024 03:59 GMT

    … to continue to grow while revenue intensity improves, driven by higher … , we see robust sales of pharmaceuticals and over-the-counter (OTC … , the pharmaceutical segment should see a robust recovery in the second half of …

  • SS Innovations International Announces Q1 2024 Company Updates 22 Apr 2024 12:00 GMT

    Significant milestones achieved for SSi Mantra Made-in-India surgical robotic system FORT LAUDERDALE, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative …

  • It's big news for these Texas towns. 22 Apr 2024 18:58 GMT

    … expected to open in the second half of 2026 and will be … our business community. The tax revenue from this endeavor will benefit … grocery pick-up area and pharmacy drive-thru. A future H … exciting from a sales tax revenue point of view, but as …

Satisfied with the content?

Continue to create your account.